CRT signs new deal with Italy’s Abiogen
2007-07-11
合作抗体
Cancer Research TechnologyCancer Research Technology, the oncology-focused development and commercialisation firm wholly owned by charity Cancer Research UKCancer Research UK, has signed an exclusive worldwide licence with Italy’s Abiogen Pharma S.p.A regarding the antibody RFB4.
The deal replaces an earlier license issued to the Pisa-based firm, and allows it to continue using RFB4, in combination with key technology from the University of Texas Southwestern Medical Center at Dallas, to develop its new therapies. In return, CRT will receive a signature fee, milestone payments and a percentage of future royalties.
RFB4, originally developed by researchers at the Royal Free Hospital School of Medicine in London, which then passed ownership rights to Imperial Cancer ResearchCancer Research Technology (before it became CRT), is an antibody against the B cell antigen CD22. CD22 is expressed in approximately 70% of B cell lymphomas and leukaemias, and therefore RFB4 has the potential to form part of future selectively-targeted therapies against such cancers. Abiogen is currently testing two such therapies in Phase I clinical trials.
Further details were not disclosed.
靶点
药物
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。